OncoSolid™ Cervical Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cervical Cancer Organoid Models

Cervical cancer is a kind of malignant disease initiated in female populations, and most of the tumor is caused by human papillomavirus infections. The commonly diagnosed cervical cancers are squamous cell carcinoma (SqCa) and adenocarcinoma (AdCa), originating from the ectocervix and the endocervix. Good models are lacking and need to be well-developing for cervical cancer studies.

Creative Biolabs has decades-years of experience in cancer study and offers cervical cancer organoid models for tumorigenesis discovery, precision medicine, and therapeutics efficacy tests using a collection of biological organoid lines that reconstitute the histological and gene expression phenotype of primary cancer.

Key Features of Cervical Cancer Organoid Models at Creative Biolabs

Workflow

Fig.1 Workflow for the establishment of cervical organoids. (Maru, et al., 2020)

Cervical Organoids Subtypes and Features

We provide cancer organoids with similar morphological and genetic features to primary cancer. The initial tumor and following matched organoids are assessed using histological and molecular methods and tools.

Representative Histological Features of Different Types of Cervical Organoids

Subtype of cancer	Morphology	Histological Architecture	Biomarker Identification
Squamous cell carcinoma (SqCa)	Dense morphology	Loss of stratification and cellular polarity vacuolated cytoplasm	Basal cells Keratinocytes Squamous cell carcinoma marker
Adenocarcinoma (AdCa)	Denser structures with prominent vacuolization	PAX8+MKI67+ endocervical origin	Secretory cell transcription marker Proliferation biomarker
HPV18-positive small cell carcinoma	Round, cystic structure	Glandular differentiation	Synaptophysin Chromogranin A CD56

Fig.2 Genetic alterations in tumor and matches organoids are analyzed. (Creative Biolabs)

Our Cervical Cancer-related CAR-T Products and Services

With extensive experience in CAR-T therapy development, Creative Biolabs provides antigen-specific CARs products, including plasmid DNA, viral vectors, CAR cells, and construction kits, for CAR-T cell anti-tumor efficacy analysis.

Target antigen	Target description	CAR-T products
Mesothelin	Mesothelin (MSLN) is overexpressed in more than 77% of cervical adenocarcinomas and is an attractive target for cervical cancer therapy.	Anti-Mesothelin CAR-T

Case Study 1

Establishing Cervical Cancer Organoid from Tiny Clinical Test Tissue
Backgrounds: Organoid model of squamous cell carcinoma (SqCa) and adenocarcinoma (AdCa) are established from tiny tumor tissue. SqCa is composed of stratified squamous-like epithelium tissue, and AdCa is lined with glandular columnar cells.
Figure.3 Brightfield image and passage generations of cervical cancer organoids. (Lõhmussaar, et al., 2021)
Figure.4 The patient-derived SqCa organoids and AdCa organoids recapitulate the histology of primary tumor tissue characterized using specific antiboies. (Lõhmussaar, et al., 2021)

Case Study 2

A Published Cervical Organoids Culture Method

Step 1: Digestion
2–3 mm tissue pieces are digested using 2 U/ml dispase II, 1 mg/ml collagenase P with 10 U DNase I for 45 min at 37°C.
Step 2: Culture Medium

Advanced Dulbecco's modified Eagle medium/F12
Human epidermal growth factor	50 ng/ml
Recombinant Mouse R-spondin1	250 ng/ml
Noggin	100 ng/ml
Y27632	10 μM
Jagged-1	1 μM
l-glutamine solution
Penicillin–streptomycin

Step 3: Cultured on Matrix
Place cell suspension on solidified Matrigel, incubated at 37°C.

Let Us Know Your Requirements

Creative Biolabs offers faster development and enhanced cultures of organoids for CAR-T anti-tumor activity evaluation. Please contact us and get more detailed information.

References

Koster, S.; et al. Modelling Chlamydia and HPV co-infection in patient-derived ectocervix organoids reveals distinct cellular reprogramming. Nat Commun. 2022, 13: 1030.
Lõhmussaar, K.; et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell stem cell. 2021, 28(8): 1380–1396.e6.
Maru, Y.; et al. Establishment and Molecular Phenotyping of Organoids from the Squamocolumnar Junction Region of the Uterine Cervix. Cancers. 2020, 12: 694.